Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia

Detalhes bibliográficos
Autor(a) principal: Gomes, A.
Data de Publicação: 2011
Outros Autores: Santos, T., Bourbon, M.
Idioma: eng
Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Texto Completo: http://hdl.handle.net/10400.18/390
Resumo: Several studies demonstrated that sdLDL are an emerging cardiovascular (CV) risk factor. The objective of this study was sdLDL measurement in patients with genetic diagnosis of Familial Hypercholesterolaemia (FH) and clinical diagnosis of Familial Combined Hyperlipidaemia (FCHL) to establish a relation between sdLDL, CV risk and the efficacy of therapeutics. Lipid profile was determined using a polyacrylamide gel electrophoresis system that separates the particles in serum that contain cholesterol. The lipidogram obtained classifies the patients as being profile A (low CV risk) or B (high CV risk) depending on the sdLDL concentration. The lipid profile was obtained from 43 FH adults and 46 FCHL adults, index and relatives. FH and FCHL patients without medication and with high sdLDL (>6mg/dl) have significant higher levels of total cholesterol, LDL and ApoB and FCHL patients also have significant higher triglycerides, compared to FH and FCHL patients with sdLDL levels under recommended values. Under medication FH patients have significant higher ApoB levels and lower HDL, and FCHL patients have significant higher total cholesterol, LDL and ApoB levels. Interestingly, 71,4% of FCHL patients under medication presented high CV risk profile, showing that statins seem not to decrease sdLDL levels and neither CV risk. Also FCHL patients are not well medicated or do not respond to usual medication to decrease cholesterol. These preliminary results indicate that sdLDL could be a good biomarker for treatment control but further studies are needed to evaluate the effect of medication in sdLDL levels in FH and FCHL patients.
id RCAP_d3c4ddfdcac0d5eb1ceb771c417188cd
oai_identifier_str oai:repositorio.insa.pt:10400.18/390
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined HyperlipidaemiaDoenças Cardio e Cérebro-vascularesSeveral studies demonstrated that sdLDL are an emerging cardiovascular (CV) risk factor. The objective of this study was sdLDL measurement in patients with genetic diagnosis of Familial Hypercholesterolaemia (FH) and clinical diagnosis of Familial Combined Hyperlipidaemia (FCHL) to establish a relation between sdLDL, CV risk and the efficacy of therapeutics. Lipid profile was determined using a polyacrylamide gel electrophoresis system that separates the particles in serum that contain cholesterol. The lipidogram obtained classifies the patients as being profile A (low CV risk) or B (high CV risk) depending on the sdLDL concentration. The lipid profile was obtained from 43 FH adults and 46 FCHL adults, index and relatives. FH and FCHL patients without medication and with high sdLDL (>6mg/dl) have significant higher levels of total cholesterol, LDL and ApoB and FCHL patients also have significant higher triglycerides, compared to FH and FCHL patients with sdLDL levels under recommended values. Under medication FH patients have significant higher ApoB levels and lower HDL, and FCHL patients have significant higher total cholesterol, LDL and ApoB levels. Interestingly, 71,4% of FCHL patients under medication presented high CV risk profile, showing that statins seem not to decrease sdLDL levels and neither CV risk. Also FCHL patients are not well medicated or do not respond to usual medication to decrease cholesterol. These preliminary results indicate that sdLDL could be a good biomarker for treatment control but further studies are needed to evaluate the effect of medication in sdLDL levels in FH and FCHL patients.Instituto Nacional de Saúde Doutor Ricardo Jorge, IPRepositório Científico do Instituto Nacional de SaúdeGomes, A.Santos, T.Bourbon, M.2012-01-17T16:28:34Z2011-062011-06-01T00:00:00Zconference objectinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10400.18/390enginfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-26T14:30:14Zoai:repositorio.insa.pt:10400.18/390Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T21:45:02.036441Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
title Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
spellingShingle Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
Gomes, A.
Doenças Cardio e Cérebro-vasculares
title_short Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
title_full Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
title_fullStr Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
title_full_unstemmed Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
title_sort Determination of sdLDL particles in patients with Familial Hyercholesterolaemia and Familial Combined Hyperlipidaemia
author Gomes, A.
author_facet Gomes, A.
Santos, T.
Bourbon, M.
author_role author
author2 Santos, T.
Bourbon, M.
author2_role author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Gomes, A.
Santos, T.
Bourbon, M.
dc.subject.por.fl_str_mv Doenças Cardio e Cérebro-vasculares
topic Doenças Cardio e Cérebro-vasculares
description Several studies demonstrated that sdLDL are an emerging cardiovascular (CV) risk factor. The objective of this study was sdLDL measurement in patients with genetic diagnosis of Familial Hypercholesterolaemia (FH) and clinical diagnosis of Familial Combined Hyperlipidaemia (FCHL) to establish a relation between sdLDL, CV risk and the efficacy of therapeutics. Lipid profile was determined using a polyacrylamide gel electrophoresis system that separates the particles in serum that contain cholesterol. The lipidogram obtained classifies the patients as being profile A (low CV risk) or B (high CV risk) depending on the sdLDL concentration. The lipid profile was obtained from 43 FH adults and 46 FCHL adults, index and relatives. FH and FCHL patients without medication and with high sdLDL (>6mg/dl) have significant higher levels of total cholesterol, LDL and ApoB and FCHL patients also have significant higher triglycerides, compared to FH and FCHL patients with sdLDL levels under recommended values. Under medication FH patients have significant higher ApoB levels and lower HDL, and FCHL patients have significant higher total cholesterol, LDL and ApoB levels. Interestingly, 71,4% of FCHL patients under medication presented high CV risk profile, showing that statins seem not to decrease sdLDL levels and neither CV risk. Also FCHL patients are not well medicated or do not respond to usual medication to decrease cholesterol. These preliminary results indicate that sdLDL could be a good biomarker for treatment control but further studies are needed to evaluate the effect of medication in sdLDL levels in FH and FCHL patients.
publishDate 2011
dc.date.none.fl_str_mv 2011-06
2011-06-01T00:00:00Z
2012-01-17T16:28:34Z
dc.type.driver.fl_str_mv conference object
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/390
url http://hdl.handle.net/10400.18/390
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
publisher.none.fl_str_mv Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833599405490438144